1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 29 SEPTEMBER 2014

Cancer Drug News 29 SEPTEMBER 2014

  • October 2014
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Amgen Vies For Swift Blinatumomab Approval
Industry Brief - TG Agrees SPA With FDA For CLL Phase III Trial
Industry Brief - Cephalon Acts To End Litigation Against Eagle
Industry Brief - Soligenix Receives FDA Clearance Of SGX301 Phase III Protocol In CTCL
Industry Brief - Spectrum Out-Licenses Three Oncology Drugs To CASI For Greater China
Industry Brief - TG Exercises Licence Option For TGR-1202
Industry Trend Analysis - Zydelig's EU Approval Puts It Temporarily Ahead Of Imbruvica
Industry Brief - CTI And Servier Sign Licensing Deal To Develop/Commercialise Pixuvri
Industry Brief - LHB589 Performs Well In Phase III Combination Trials
Industry Brief - NOXXON Receives FDA ODD For Olaptesed Pegol
Industry Trend Analysis - BI Enhances Oncology Pipeline With CureVac Agreement
Industry Brief - Telormedix Secures European Patent Covering Vesimune
Industry Trend Analysis - Boehringer Ingelheim Close To Market With Second Oncology Drug
Industry Brief - ODM-201 Phase III Trial Initiated In Non-Metastatic Castration-Resistant PCA
Industry Brief - Mologen Initiates MGN1703 Phase III Study In MCRC
Industry Brief - FDA Lifts Clinical Hold On PEGPH20 Phase Ib/II Advanced Pancreatic Cancer Trial
Industry Brief - Oncolytics Reports Patient Data From Phase II MPC Study
Industry Brief - PharmaEngine/Merrimack Amend Licence Agreement For MM-398
Industry Brief - Rexahn's RX-3117 Gains FDA ODD For PC
Industry Brief - Abraxane Gains Swissmedic Approval For MPC/MBC
Industry Brief - Baxter/Merrimack Sign Ex-US Licensing Deal For MM-398
Industry Trend Analysis - Cancer Vaccine Gains First UK Promising Innovative Medicine Designation
Industry Brief - FDA Grants ODD To MabVax' Neuroblastoma Vaccine
Industry Brief - ImmunoCellular Provides Update On ICT-107/DC-Based Vaccines
Industry Brief - Health Canada Approves Yervoy As First-Line Treatment In Advanced Melanoma
Industry Brief - IDMC Recommends Continuation Of Threshold's TH-302 Phase III Trial In Advanced STS
Industry Brief - BeiGene Receives Clinical Milestone Payment For Development Of BGB-290
Industry Brief - Merck Serono/Sutro Collaborate To Develop ADCs
Industry Trend Analysis - Acquisition Of Lilly's Enzastaurin Is First Step For Budding Company Denovo
Industry Brief - 3SBio Gains Exclusive Chinese Licence For JenKem's PEG-Irinotecan
Industry Trend Analysis - Next-Generation Sequencing Changing The Face Of Personalised Medicine
Industry Brief - MedImmune/Cancer Research UK Collaborate To Develop Cancer Treatments
Industry Trend Analysis - Bayer's De-Diversification Presents Opportunities For Oncology Segment
Industry Trend Analysis - Merck KGaA On Track With Pharma Strategy
Industry Trend Analysis - Daiichi Sankyo Fuels Oncology Pipeline With Ambit Acquisition
Industry Trend Analysis - Adaptimmune Financing Highlights Immuno-Oncology Trend

Table Of Contents

Cancer Drug News 29 SEPTEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.